JPMorgan Healthcare Conference is the biggest health care investing event of the year. About 9,000 attendees walking in and out of meeting rooms here at the St. Francis — Westin in San Francisco. This is where attendees (investors) figure out where they’re going to put their money in the year.
The “Mad Money” host outlines what he plans to watch in the days to come.
Jim Cramer’s researcher, Nicole Urken, looks into the big gain on Pharmasset and highlights some other well-positioned biotechs.
Cramer makes the call on viewers' favorite stocks.
Cramer explains why he prefers this pharma over Pfizer's stock.
Pfizer may have a lower multiple than Celgene, says Mad Money's Cramer, but it also has much slower growth, which is why PFE is expensive at these levels, and CELG is dirt cheap versus its prospect.
Thursday’s recovery from EU debt crisis puts focus back on fundamentals
Find out what names are in Cramer's "Game Plan."
With hundreds of companies reporting earnings, find out what names are in the “Mad Money” host’s “Game Plan.”
Traditionally Q4 is the best quarter of the year. But where can you possibly find opportunity in a market like this one?
Good bye Q3 and good riddance. Don’t let the door hit you in the behind. Now, how can you profit as we head into Q4?
Find out what earnings and conferences are in Cramer's "Game Plan" for next week.
If you hold for a while, history suggests it pays to establish new long positions in tandem with insider purchases.
Find out what Cramer expects of these two names when they report before the open Wednesday.
The “Mad Money” host reveals the 13 earnings reports he plans to monitor.
The biotech company's top executive discusses its product line, future prospects and the biotech industry in general.
Celgene CEO Bob Hugin discusses his company's latest drugs, with Mad Money host Jim Cramer.
Each quarter near the end of the earnings season, CNBC.com publishes a list of 20 stocks in the S&P 500 trading at the greatest premiums or discounts to their analysts’ consensus target prices.
The markets have doubled from the March 2009 bottom and have come a long way since, so investors should be defensive, said William Muggia, president, CEO and CIO of Westfield Capital Management.
The picks for your portfolio, with William Muggia, Touchstone Growth Opportunities Fund.